Astera Labs, Inc. Files S-1 Registration Statement
Ticker: ALAB · Form: S-1 · Filed: Feb 21, 2024 · CIK: 1736297
| Field | Detail |
|---|---|
| Company | Astera Labs, INC. (ALAB) |
| Form Type | S-1 |
| Filed Date | Feb 21, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $116M, $17.2 billion, $27.4 billion, $79.9 million, $115.8 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: IPO, S-1 Filing, Astera Labs, Semiconductors, Emerging Growth Company
TL;DR
<b>Astera Labs, Inc. has submitted an S-1 filing, signaling its intent to go public.</b>
AI Summary
Astera Labs, Inc. (ALAB) filed a IPO Registration (S-1) with the SEC on February 21, 2024. Astera Labs, Inc. has filed an S-1 registration statement with the SEC. The filing is dated February 21, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 2901 Tasman Drive, Suite 205, Santa Clara, CA 95054. Astera Labs, Inc. is classified as an emerging growth company and a non-accelerated filer.
Why It Matters
For investors and stakeholders tracking Astera Labs, Inc., this filing contains several important signals. This S-1 filing is a prerequisite for Astera Labs, Inc. to conduct an Initial Public Offering (IPO), allowing it to raise capital from public investors. The detailed information within the S-1 provides potential investors with crucial insights into the company's business, financial condition, and risks, enabling informed investment decisions.
Risk Assessment
Risk Level: medium — Astera Labs, Inc. shows moderate risk based on this filing. The company is an emerging growth company and a non-accelerated filer, which may indicate a less established financial history or operational scale compared to larger, more mature companies.
Analyst Insight
Monitor future filings for detailed financial performance, revenue growth, and competitive landscape analysis as Astera Labs, Inc. prepares for its IPO.
Key Numbers
- 333-277205 — SEC File Number (SEC File Number for the registration statement)
- 823437062 — IRS Number (IRS Employer Identification Number)
- 3674 — SIC Code (Standard Industrial Classification Code for Semiconductors & Related Devices)
Key Players & Entities
- Astera Labs, Inc. (company) — Registrant Name
- Securities and Exchange Commission (regulator) — Filing body
- Delaware (company) — State of Incorporation
- 2901 Tasman Drive, Suite 205 (company) — Principal Executive Offices Address
- Santa Clara, CA 95054 (company) — Principal Executive Offices City, State, Zip
- Jitendra Mohan (person) — Co-Founder and Chief Executive Officer
- Goodwin Procter LLP (company) — Legal Counsel
- Simpson Thacher & Bartlett LLP (company) — Legal Counsel
FAQ
When did Astera Labs, Inc. file this S-1?
Astera Labs, Inc. filed this IPO Registration (S-1) with the SEC on February 21, 2024.
What is a S-1 filing?
A S-1 is a registration statement for initial public offerings, containing the prospectus with business description, financials, and risk factors. This particular S-1 was filed by Astera Labs, Inc. (ALAB).
Where can I read the original S-1 filing from Astera Labs, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Astera Labs, Inc..
What are the key takeaways from Astera Labs, Inc.'s S-1?
Astera Labs, Inc. filed this S-1 on February 21, 2024. Key takeaways: Astera Labs, Inc. has filed an S-1 registration statement with the SEC.. The filing is dated February 21, 2024.. The company is incorporated in Delaware and its fiscal year ends on December 31..
Is Astera Labs, Inc. a risky investment based on this filing?
Based on this S-1, Astera Labs, Inc. presents a moderate-risk profile. The company is an emerging growth company and a non-accelerated filer, which may indicate a less established financial history or operational scale compared to larger, more mature companies.
What should investors do after reading Astera Labs, Inc.'s S-1?
Monitor future filings for detailed financial performance, revenue growth, and competitive landscape analysis as Astera Labs, Inc. prepares for its IPO. The overall sentiment from this filing is neutral.
How does Astera Labs, Inc. compare to its industry peers?
Astera Labs operates in the semiconductor industry, specifically focusing on products for data centers and high-performance computing.
Are there regulatory concerns for Astera Labs, Inc.?
The S-1 filing is a regulatory requirement under the Securities Act of 1933 for companies intending to offer securities to the public.
Industry Context
Astera Labs operates in the semiconductor industry, specifically focusing on products for data centers and high-performance computing.
Regulatory Implications
The S-1 filing is a regulatory requirement under the Securities Act of 1933 for companies intending to offer securities to the public.
What Investors Should Do
- Review the full S-1 filing for detailed financial statements and risk factors.
- Analyze the company's business model and competitive positioning within the semiconductor market.
- Track the IPO date and initial trading performance of Astera Labs, Inc. (ALAB).
Key Dates
- 2024-02-20: Filing Date — Date the S-1 registration statement was filed with the SEC.
Year-Over-Year Comparison
This is the initial S-1 filing for Astera Labs, Inc., indicating it is preparing for its first public offering.
Filing Stats: 4,399 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-02-20 21:51:49
Key Financial Figures
- $116M — Hyperscalers and Al Platform Providers $116MM 2023 Revenue Millions of Devices Shipp
- $17.2 billion — owing total addressable market (TAM) of $17.2 billion. Specifically, our technology and produ
- $27.4 billion — t. We believe that our TAM will grow to $27.4 billion by 2027, and we expect to address an in
- $79.9 million — of Aries in 2020. Our revenue grew from $79.9 million in 2022 to $115.8 million in 2023, driv
- $115.8 million — enue grew from $79.9 million in 2022 to $115.8 million in 2023, driven by a significant increa
- $58.3 million — annual basis. We incurred net losses of $58.3 million in 2022 and $26.3 million in 2023. As o
- $26.3 million — net losses of $58.3 million in 2022 and $26.3 million in 2023. As of December 31, 2022 and 20
- $99.1 million — 2023, we had an accumulated deficit of $99.1 million and $125.4 million, respectively. Durin
- $125.4 m — ccumulated deficit of $99.1 million and $125.4 million, respectively. During the years e
- $35.9 million — r cash used in operating activities was $35.9 million and $12.7 million, respectively. Indu
- $12.7 m — rating activities was $35.9 million and $12.7 million, respectively. Industry Backgro
Filing Documents
- d285484ds1.htm (S-1) — 1913KB
- d285484dex31.htm (EX-3.1) — 96KB
- d285484dex32.htm (EX-3.2) — 25KB
- d285484dex33.htm (EX-3.3) — 74KB
- d285484dex34.htm (EX-3.4) — 119KB
- d285484dex42.htm (EX-4.2) — 339KB
- d285484dex101.htm (EX-10.1) — 150KB
- d285484dex105.htm (EX-10.5) — 38KB
- d285484dex106.htm (EX-10.6) — 13KB
- d285484dex107.htm (EX-10.7) — 14KB
- d285484dex108.htm (EX-10.8) — 13KB
- d285484dex109.htm (EX-10.9) — 13KB
- d285484dex1010.htm (EX-10.10) — 59KB
- d285484dex1011.htm (EX-10.11) — 20KB
- d285484dex1012.htm (EX-10.12) — 54KB
- d285484dex1013.htm (EX-10.13) — 102KB
- d285484dex211.htm (EX-21.1) — 3KB
- d285484dex231.htm (EX-23.1) — 1KB
- d285484dexfilingfees.htm (EX-FILING FEES) — 16KB
- g285484g00b01.jpg (GRAPHIC) — 376KB
- g285484g00b02.jpg (GRAPHIC) — 288KB
- g285484g01a01.jpg (GRAPHIC) — 133KB
- g285484g02a55.jpg (GRAPHIC) — 223KB
- g285484g03c02.jpg (GRAPHIC) — 237KB
- g285484g03c04.jpg (GRAPHIC) — 503KB
- g285484g04p11.jpg (GRAPHIC) — 195KB
- g285484g19a10.jpg (GRAPHIC) — 120KB
- g285484g19a20.jpg (GRAPHIC) — 63KB
- g285484g31x42.jpg (GRAPHIC) — 176KB
- g285484g34u90.jpg (GRAPHIC) — 110KB
- g285484g35v79.jpg (GRAPHIC) — 119KB
- g285484g38a00.jpg (GRAPHIC) — 167KB
- g285484g40p00.jpg (GRAPHIC) — 145KB
- g285484g43p01.jpg (GRAPHIC) — 107KB
- g285484g51k00.jpg (GRAPHIC) — 118KB
- g285484g51k20.jpg (GRAPHIC) — 131KB
- g285484g77f75.jpg (GRAPHIC) — 115KB
- g285484page18a.jpg (GRAPHIC) — 5KB
- 0001193125-24-040419.txt ( ) — 7655KB
RISK FACTORS
RISK FACTORS 17 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 54 INDUSTRY AND MARKET DATA 56
USE OF PROCEEDS
USE OF PROCEEDS 57 DIVIDEND POLICY 58 CAPITALIZATION 59
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 64 A LETTER FROM OUR FOUNDERS 86
BUSINESS
BUSINESS 88 MANAGEMENT 115
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 122 Page CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 132 PRINCIPAL AND SELLING STOCKHOLDERS 137
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 140 SHARES ELIGIBLE FOR FUTURE SALE 146 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 149
UNDERWRITING
UNDERWRITING 154 LEGAL MATTERS 162 EXPERTS 162 WHERE YOU CAN FIND ADDITIONAL INFORMATION 162 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 Through and including , 2024 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus, or contained in any free writing prospectus filed by us with the Securities and Exchange Commission (the SEC). Neither we, the selling stockholders, nor any of the underwriters have authorized anyone to provide any information or make any representations other than those contained in this prospectus, any amendment or supplement to this prospectus, or in any free writing prospectus we have prepared. We, the selling stockholders, and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, any amendment or supplement to this prospectus, or any free writing prospectus, is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus, any amendment or supplement to this prospectus, or any applicable free writing prospectus, as the case may be, or of any sale of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. For investors outside of the United